GALIDESIVIR
Galidesivir is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | GALIDESIVIR |
| INN | galidesivir |
| Description | Galidesivir (BCX4430, immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.
|
| Classification | Small molecule |
| Drug class | antivirals: adenosine analogs acting as RNA polymerase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12 |
Identifiers
| PDB | — |
| CAS-ID | 222631-44-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1236524 |
| ChEBI ID | — |
| PubChem CID | 69211190 |
| DrugBank | — |
| UNII ID | OLF97F86A7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use